Lakefront Biotherapeutics (LKFT) Depreciation & Amortization (CF) (2016 - 2022)

Lakefront Biotherapeutics (LKFT) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $6.3 million the latest figure, recorded in Q1 2022.

• Quarterly Depreciation & Amortization (CF) rose 9.9% year-over-year to $6.3 million in Q1 2022, while the trailing twelve-month figure through Mar 2026 was -$0.0 (changed 0.0% YoY) and the FY2017 annual result came in at $5.2 million, up 9.36% from the prior year.
• Depreciation & Amortization (CF) climbed to $6.3 million in Q1 2022 per LKFT's latest filing, from $5.7 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for LKFT reached as high as $2.7 billion in Q2 2018 and fell as low as -$2.7 billion in Q3 2018.
• A 5-year average of $3.5 million and a median of $4.8 million in 2020 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2018 — Depreciation & Amortization (CF) dropped 4.83% — and 2019, when it soared 81.68%.
• Year by year, Depreciation & Amortization (CF) stood at -$2.7 billion in 2018, then surged by 100.12% to $3.1 million in 2019, then jumped by 51.89% to $4.8 million in 2020, then climbed by 19.81% to $5.7 million in 2021, then rose by 9.9% to $6.3 million in 2022.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $6.3 million, $5.7 million, and $4.8 million for Q1 2022, Q1 2021, and Q1 2020 respectively.